Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/33241760/ below:

The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada

Affiliations

• ¹ Independent Consultant, Toronto, Canada.
• ² 282299Sunnybrook Research Institute, Toronto, Canada.
• ³ Departments of Medical Biophysics and Medical Imaging, University of Toronto, Toronto, Canada.
• ⁴ Department of Cancer Epidemiology and Prevention Research, 3146Alberta Health Services, Calgary, Canada.
• ⁵ British Columbia Cancer Research, Vancouver, Canada.
• ⁶ 6360Statistics Canada, Ottawa, Canada.
• ⁷ University of Toronto, Toronto, Canada.
• ⁸ Forzani & MacPhail Colon Cancer Screening Centre, 3146Alberta Health Services, Calgary, Canada.
• ⁹ Departments of Medicine and Community Health Sciences, Cumming School of Medicine, 2129University of Calgary, Calgary, Canada.
• ¹⁰ Departments of Oncology and Community Health Sciences, Cumming School of Medicine, 2129University of Calgary, Calgary, Canada.

• PMID: 33241760
• PMCID: PMC7691762
• DOI: 10.1177/0969141320974711

Item in Clipboard

Jean He Yong et al. J Med Screen. 2021 Jun.

• ¹ Independent Consultant, Toronto, Canada.
• ² 282299Sunnybrook Research Institute, Toronto, Canada.
• ³ Departments of Medical Biophysics and Medical Imaging, University of Toronto, Toronto, Canada.
• ⁴ Department of Cancer Epidemiology and Prevention Research, 3146Alberta Health Services, Calgary, Canada.
• ⁵ British Columbia Cancer Research, Vancouver, Canada.
• ⁶ 6360Statistics Canada, Ottawa, Canada.
• ⁷ University of Toronto, Toronto, Canada.
• ⁸ Forzani & MacPhail Colon Cancer Screening Centre, 3146Alberta Health Services, Calgary, Canada.
• ⁹ Departments of Medicine and Community Health Sciences, Cumming School of Medicine, 2129University of Calgary, Calgary, Canada.
• ¹⁰ Departments of Oncology and Community Health Sciences, Cumming School of Medicine, 2129University of Calgary, Calgary, Canada.

• PMID: 33241760
• PMCID: PMC7691762
• DOI: 10.1177/0969141320974711

Item in Clipboard

Background: Population-based cancer screening can reduce cancer burden but was interrupted temporarily due to the COVID-19 pandemic. We estimated the long-term clinical impact of breast and colorectal cancer screening interruptions in Canada using a validated mathematical model.

Methods: We used the OncoSim breast and colorectal cancers microsimulation models to explore scenarios of primary screening stops for 3, 6, and 12 months followed by 6-24-month transition periods of reduced screening volumes. For breast cancer, we estimated changes in cancer incidence over time, additional advanced-stage cases diagnosed, and excess cancer deaths in 2020-2029. For colorectal cancer, we estimated changes in cancer incidence over time, undiagnosed advanced adenomas and colorectal cancers in 2020, and lifetime excess cancer incidence and deaths.

Results: Our simulations projected a surge of cancer cases when screening resumes. For breast cancer screening, a three-month interruption could increase cases diagnosed at advanced stages (310 more) and cancer deaths (110 more) in 2020-2029. A six-month interruption could lead to 670 extra advanced cancers and 250 additional cancer deaths. For colorectal cancers, a six-month suspension of primary screening could increase cancer incidence by 2200 cases with 960 more cancer deaths over the lifetime. Longer interruptions, and reduced volumes when screening resumes, would further increase excess cancer deaths.

Conclusions: Interruptions in cancer screening will lead to additional cancer deaths, additional advanced cancers diagnosed, and a surge in demand for downstream resources when screening resumes. An effective strategy is needed to minimize potential harm to people who missed their screening.

Keywords: COVID-19; colo-rectal cancer screening; interruption of screening; mammography screening.

PubMed Disclaimer

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

(a) Projected number of incident…

(a) Projected number of incident cases in Canada (*invasive cancer and DCIS combined)…

(a) Projected number of incident cases in Canada (*invasive cancer and DCIS combined) in 2018–2026 for the no interruption scenario, 3-, 6-, and 12-month interruption scenarios. (b) Projected cumulative excess breast cancer deaths (95% confidence intervals) for 3-, 6-, and 12-month interruptions. (c) Projected cumulative excess breast cancer deaths for 6-month interruption followed by 6-, 12-, and 24-months of 50% reduced capacity transition periods. (d) Projected cumulative excess breast cancer deaths for 12-month interruption followed by 12- and 24-months of 50% reduced capacity transition periods.

(a) Projected number of incident…

(a) Projected number of incident colorectal cancer cases in Canada in 2018–2026 for…

(a) Projected number of incident colorectal cancer cases in Canada in 2018–2026 for the no interruption scenario, 3-, 6-, and 12-month interruption scenarios. (b) Projected cumulative excess colorectal cancer deaths (95% confidence intervals) for 3-, 6-, and 12-month interruptions. (c) Projected cumulative excess colorectal cancer deaths for 6-month interruption followed by 6-, 12-, and 18-months of 50% reduced capacity transition periods. (d) Projected cumulative excess colorectal cancer deaths for 12-month interruption followed by 12- and 24-months of 50% reduced capacity transition periods.

(a) Impact of interruption to…

(a) Impact of interruption to mammography on additional breast cancers diagnosed between 2020…

(a) Impact of interruption to mammography on additional breast cancers diagnosed between 2020 and 2029 at a later stage resulting from a 3-, 6-, and 12-month service interruption in Canada. (b) Lifetime impact of colorectal cancer screening interruptions on additional colorectal cancers, stratified by cancer stages, resulting from a 3-, 6-, and 12-month interruptions.

• Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.

  de Jonge L, Worthington J, van Wifferen F, Iragorri N, Peterse EFP, Lew JB, Greuter MJE, Smith HA, Feletto E, Yong JHE, Canfell K, Coupé VMH, Lansdorp-Vogelaar I; COVID-19 and Cancer Global Modelling Consortium working group 2. de Jonge L, et al. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):304-314. doi: 10.1016/S2468-1253(21)00003-0. Epub 2021 Feb 3. Lancet Gastroenterol Hepatol. 2021. PMID: 33548185 Free PMC article.

• Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.

  van Wifferen F, de Jonge L, Worthington J, Greuter MJE, Lew JB, Nadeau C, van den Puttelaar R, Feletto E, Yong JHE, Lansdorp-Vogelaar I, Canfell K, Coupé VMH; COVID-19 and Cancer Global Modelling Consortium (CCGMC) working group 2. van Wifferen F, et al. J Med Screen. 2022 Jun;29(2):72-83. doi: 10.1177/09691413211056777. Epub 2021 Dec 3. J Med Screen. 2022. PMID: 35100894 Free PMC article.

• COVID-related disruptions to colorectal cancer screening, diagnosis, and treatment could increase cancer Burden in Australia and Canada: A modelling study.

  Worthington J, Sun Z, Fu R, Lew JB, Chan KKW, Li Q, Eskander A, Hui H, McLoughlin K, Caruana M, Peacock S, Yong JHE, Canfell K, Feletto E, Malagón T. Worthington J, et al. PLoS One. 2024 Apr 1;19(4):e0296945. doi: 10.1371/journal.pone.0296945. eCollection 2024. PLoS One. 2024. PMID: 38557758 Free PMC article.

• Utility of polygenic risk scores in UK cancer screening: a modelling analysis.

  Huntley C, Torr B, Sud A, Rowlands CF, Way R, Snape K, Hanson H, Swanton C, Broggio J, Lucassen A, McCartney M, Houlston RS, Hingorani AD, Jones ME, Turnbull C. Huntley C, et al. Lancet Oncol. 2023 Jun;24(6):658-668. doi: 10.1016/S1470-2045(23)00156-0. Epub 2023 May 10. Lancet Oncol. 2023. PMID: 37178708 Review.

• A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis.

  Li T, Nickel B, Ngo P, McFadden K, Brennan M, Marinovich ML, Houssami N. Li T, et al. Breast. 2023 Feb;67:78-88. doi: 10.1016/j.breast.2023.01.001. Epub 2023 Jan 5. Breast. 2023. PMID: 36646004 Free PMC article. Review.

• Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Cervical Cancer Screening in Gynecological Practices in Germany.

  Gremke N, Griewing S, Felgentreff M, Kostev K, Kalder M. Gremke N, et al. Cancers (Basel). 2022 Oct 2;14(19):4820. doi: 10.3390/cancers14194820. Cancers (Basel). 2022. PMID: 36230743 Free PMC article.

• Evaluating Real World Health System Resource Utilization and Costs for a Risk-Based Breast Cancer Screening Approach in the Canadian PERSPECTIVE Integration and Implementation Project.

  Seung SJ, Mittmann N, Ante Z, Liu N, Blackmore KM, Richard ES, Wong A, Walker MJ, Earle CC, Simard J, Chiarelli AM. Seung SJ, et al. Cancers (Basel). 2024 Sep 18;16(18):3189. doi: 10.3390/cancers16183189. Cancers (Basel). 2024. PMID: 39335160 Free PMC article.

• Has the COVID-19 pandemic changed the clinical picture and tumour stage at the time of presentation of patients with colorectal cancer? A retrospective cohort study.

  Cano-Valderrama O, Sánchez-Santos R, Vigorita V, Paniagua M, Flores E, Garrido L, Facal C, Ruano A, San-Ildefonso A, Moncada E. Cano-Valderrama O, et al. Cir Esp. 2023 Feb;101(2):90-96. doi: 10.1016/j.ciresp.2022.02.001. Epub 2022 Feb 11. Cir Esp. 2023. PMID: 35169328 Free PMC article.

• The impact of delaying colonoscopies during the COVID-19 pandemic on colorectal cancer detection and prevention.

  Holland J, Cwintal M, Rigas G, Pang AJ, Vasilevsky CA, Morin N, Ghitulescu G, Faria J, Boutros M. Holland J, et al. Surg Endosc. 2022 Dec;36(12):9364-9373. doi: 10.1007/s00464-022-09211-z. Epub 2022 Apr 15. Surg Endosc. 2022. PMID: 35428894 Free PMC article.

• Colorectal Cancer Screening: Impact of COVID-19 Pandemic and Possible Consequences.

  Harber I, Zeidan D, Aslam MN. Harber I, et al. Life (Basel). 2021 Nov 26;11(12):1297. doi: 10.3390/life11121297. Life (Basel). 2021. PMID: 34947828 Free PMC article. Review.

1. 1. World Health Organization. Coronavirus (COVID-19), https://covid19.who.int/ (2020, accessed 10 October 2020).
2. 1. Government of Canada. Coronavirus disease (COVID-19): outbreak update, www.canada.ca/en/public-health/services/diseases/coronavirus-disease-cov... (2020, accessed 10 October 2020).
3. 1. Brenner DR, Weir HK, Demers AA, et al..; Canadian Cancer Statistics Advisory Committee. Projected estimates of cancer in Canada in 2020. CMAJ 2020; 192: E199–E205. - PMC - PubMed
4. 1. Canadian Partnership Against Cancer. 2019–2029 Canadian strategy for cancer control. Toronto, Canada: Canadian Partnership Against Cancer, 2019.
5. 1. Canadian Partnership Against Cancer. Colorectal cancer screening in Canada: Environmental scan. Toronto, Canada: Canadian Partnership Against Cancer, 2018.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3